IP Verse

Use Of Low Dose Il-2 For Treating Autoimmune - Related Or Inflammatory Disorders - EP2683395

The patent EP2683395 was granted to Assistance Publique Hpitaux DE Paris on Aug 1, 2018. The application was originally filed on Mar 9, 2012 under application number EP12708029A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2683395

ASSISTANCE PUBLIQUE HPITAUX DE PARIS
Application Number
EP12708029A
Filing Date
Mar 9, 2012
Status
Granted And Under Opposition
Jun 29, 2018
Grant Date
Aug 1, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STRAWMANApr 30, 2019MEWBURN ELLIS -

Patent Citations (26) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0109748
DESCRIPTIONEP0118617
DESCRIPTIONEP0136489
DESCRIPTIONEP0200280
DESCRIPTIONUS4530787
DESCRIPTIONUS4604377
DESCRIPTIONUS4656132
DESCRIPTIONUS4748234
DESCRIPTIONUS4752585
INTERNATIONAL-SEARCH-REPORTEP0262802
INTERNATIONAL-SEARCH-REPORTUS5466447
INTERNATIONAL-SEARCH-REPORTWO02078624
INTERNATIONAL-SEARCH-REPORTWO2007084651
INTERNATIONAL-SEARCH-REPORTWO2010049438
OPPOSITIONEP0262802
OPPOSITIONUS2011150826
OPPOSITIONUS5466447
OPPOSITIONWO02078624
OPPOSITIONWO2005007121
OPPOSITIONWO2007084651
OPPOSITIONWO2009112502
OPPOSITIONWO2010049438
OPPOSITIONWO2010085495
OPPOSITIONWO9114444
OPPOSITIONWO9918992
OPPOSITIONWO9926660

Non-Patent Literature (NPL) Citations (18) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Assistance publique-Hôpitaux de Paris, "Clinical trial NCT01353833, Dose-effect relationship of low dose IL-2 versus placebo in Type 1 diabetes.", (20110513), pages 1 - 5, URL: http://clinicaltrials.gov/show/NCT01353833, (20120424), XP002674645-
OPPOSITION- Grinberg-Bleyer et al., "IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells", The Journal of Experimental Medicine, (20100801), vol. 207, no. 0, pages 1871 - 1878, XP002650094-
OPPOSITION- HANK et al., "Distinct Clinical and Laboratory Activity of Two Recombinant Interleukin-2 Preparations", Clinical Cancer Research, (19990000), vol. 5, pages 281 - 289, XP055590425-
OPPOSITION- LONG et al., "Defects in IL-2R Signaling Contribute to Diminished Maintenance of FOXP3 Expression in CD4 + CD25+ Regulatory T-Cells of Type 1Diabetic Subjects", Diabetes, (20100000), vol. 59, pages 407 - 415, XP055590405-
OPPOSITION- NCT00525889 -ClinicalTrials.gov-
OPPOSITION- YANG et al., "Natural Variation in Interleukin-2 Sensitivity Influences Regulatory T-Cell Frequency and Function in Individuals With Long-standing Type 1 Diabetes (manuscript DB15-0516.R1)", Diabetes publish ahead of print, (20150000), pages 1 - 47, XP055590598-
OPPOSITION- TANG et al., "Central Role of Defective lnterleukin-2 Production in the Triggering of Islet Autoimm une Destruction", Immunity, (20080000), vol. 28, pages 687 - 697, XP055590422
OPPOSITION- ROSENZWAJG et al., "Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients", J. Autoimmunity, (20150000), vol. 58, pages 48 - 58, XP029204247
OPPOSITION- HARTEMANN et al., "Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial", Lancet Diabetes Endocrinol, (20130000), vol. 1, pages 295 - 305, XP055590288
OPPOSITION- YAMANOUCHI et al., "Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity", Nat Genet, (20070000), vol. 39, pages 329 - 337, XP055084274
OPPOSITION- DENDROU et al., "Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource", Nat Genet, (20090000), vol. 41, pages 1011 - 1015, XP055590586
OPPOSITION- Dendrou et al., "Supplementary information to Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource", Nat. Genet., vol. 41, (20090900), pages 1 - 19, XP055590588
OPPOSITION- KLEIN et al., "Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines", OncoImmunology,, (20170000), vol. 6, no. 3, pages 1 - 15, XP055489641
OPPOSITION- VELLA et al., "Localization of a Type 1 Diabetes Locus in the IL2RA/CD25 Region by Use of Tag Single-Nucleotide Polymorphisms", Am J Hum Genet, (20050000), vol. 76, pages 773 - 779, XP055590582
OPPOSITION- LYONS et al., "Congenic Mapping of the Type 1 Dia betes Locus, ldd3, to a 780-kb Region of Mouse Chromosom e 3: Identifica tion of a Candidate Segment of Ancestral DNA by Haplotype Mapping", Genome Res, (20000000), vol. 10, pages 446 - 453, XP055590576
OPPOSITION- D'HENNEZEL et al., "IL-2 as a therapeutic target for the restoration of Foxp3+ regulatory T cell function in organ-specific autoimmunity: implications in pathophysiology and translation to human disease", J. Translational Medicine, (20100000), vol. 8, pages 1 - 11, XP021088835
OPPOSITION- YU et al., "Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanismssupport the use of low-dose IL-2 therapy in Type-1 diabetes", Diabetes Publish ahead of print, (20150000), vol. 64, pages 1 - 43, XP055590602
OPPOSITION- GARG et al., "Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function.", J. Immunol, (20120000), vol. 188, pages 4644 - 4653, XP055590408

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents